Australia - English - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - metformin hydrochloride, quantity: 850 mg - tablet, film coated - excipient ingredients: maize starch; povidone; colloidal anhydrous silica; magnesium stearate; hypromellose; titanium dioxide; propylene glycol; macrogol 6000; purified talc; sodium starch glycollate type a - metformin is indicated in the treatment of type 2 diabetes mellitus in adults, children from 10 years of age and adolescents, particularly in overweight patients, when dietary management and exercise alone does not result in adequate glycaemic control. for adult patients, metformin may be used as initial treatment or in sulfonylurea failures either alone or in combination with a sulfonylurea and other oral agents or as adjuvant therapy in insulin requiring type 2 diabetes.

Australia - English - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - metformin hydrochloride, quantity: 1000 mg - tablet, film coated - excipient ingredients: maize starch; povidone; colloidal anhydrous silica; magnesium stearate; hypromellose; titanium dioxide; propylene glycol; macrogol 6000; purified talc; sodium starch glycollate type a - metformin is indicated in the treatment of type 2 diabetes mellitus in adults, children from 10 years of age and adolescents, particularly in overweight patients, when dietary management and exercise alone does not result in adequate glycaemic control. for adult patients, metformin may be used as initial treatment or in sulfonylurea failures either alone or in combination with a sulfonylurea and other oral agents or as adjuvant therapy in insulin requiring type 2 diabetes.

Australia - English - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - escitalopram oxalate, quantity: 25.548 mg - tablet, film coated - excipient ingredients: croscarmellose sodium; maize starch; magnesium stearate; mannitol; microcrystalline cellulose; titanium dioxide; hypromellose; macrogol 6000 - treatment of major depression. ,treatment of social anxiety disorder (social phobia). ,treatment of generalised anxiety disorder. ,treatment of obsessive-compulsive disorder.

Australia - English - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - escitalopram oxalate, quantity: 12.774 mg - tablet, film coated - excipient ingredients: maize starch; microcrystalline cellulose; croscarmellose sodium; magnesium stearate; mannitol; titanium dioxide; hypromellose; macrogol 6000 - treatment of major depression. ,treatment of social anxiety disorder (social phobia). ,treatment of generalised anxiety disorder. ,treatment of obsessive-compulsive disorder.

Australia - English - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - ambrisentan, quantity: 5 mg - tablet, film coated - excipient ingredients: lactose monohydrate; microcrystalline cellulose; croscarmellose sodium; magnesium stearate; titanium dioxide; purified talc; allura red ac aluminium lake; polyvinyl alcohol; macrogol 3350; lecithin - ambrisentan is indicated for the treatment of: - idiopathic pulmonary arterial hypertension (pah), - pulmonary artrial hypertension associated with connective tissue disease (pah-ctd),,in patients with who functional class ii, iii or iv symptoms.

Australia - English - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - ambrisentan, quantity: 10 mg - tablet, film coated - excipient ingredients: lactose monohydrate; microcrystalline cellulose; croscarmellose sodium; magnesium stearate; titanium dioxide; purified talc; allura red ac aluminium lake; polyvinyl alcohol; macrogol 3350; lecithin - ambrisentan is indicated for the treatment of: - idiopathic pulmonary arterial hypertension (pah), - pulmonary artrial hypertension associated with connective tissue disease (pah-ctd),,in patients with who functional class ii, iii or iv symptoms.

Australia - English - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - tadalafil, quantity: 20 mg - tablet - excipient ingredients: sodium lauryl sulfate; croscarmellose sodium; magnesium stearate; lactose monohydrate; hyprolose; microcrystalline cellulose; titanium dioxide; hypromellose; triacetin; iron oxide yellow; iron oxide red - tadalis is indicated in adults for the treatment of pulmonary arterial hypertension (pah) classified as who functional class ii and iii, to improve exercise capacity. efficacy has been shown in idiopathic pah (ipah) and in pah related to collagen vascular disease.

Australia - English - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - tadalafil, quantity: 2.5 mg - tablet, film coated - excipient ingredients: sodium lauryl sulfate; hyprolose; croscarmellose sodium; microcrystalline cellulose; lactose monohydrate; magnesium stearate; titanium dioxide; hypromellose; purified talc; triacetin; iron oxide yellow; iron oxide red - tadacip is indicated for the treatment of: ? erectile dysfunction (ed) in adult males ? moderate to severe lower urinary tract symptoms (luts) associated with benign prostatic hyperplasia (bph) in adult males

Australia - English - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - tadalafil, quantity: 5 mg - tablet - excipient ingredients: microcrystalline cellulose; magnesium stearate; sodium lauryl sulfate; hyprolose; lactose monohydrate; croscarmellose sodium; titanium dioxide; hypromellose; purified talc; triacetin; iron oxide yellow; iron oxide red - tadacip is indicated for the treatment of: ? erectile dysfunction (ed) in adult males ? moderate to severe lower urinary tract symptoms (luts) associated with benign prostatic hyperplasia (bph) in adult males

Australia - English - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - tadalafil, quantity: 20 mg - tablet - excipient ingredients: lactose monohydrate; sodium lauryl sulfate; microcrystalline cellulose; croscarmellose sodium; magnesium stearate; hyprolose; titanium dioxide; hypromellose; triacetin; iron oxide yellow - tadacip is indicated for the treatment of: ? erectile dysfunction (ed) in adult males ? moderate to severe lower urinary tract symptoms (luts) associated with benign prostatic hyperplasia (bph) in adult males